Inclusion Criteria:

          -  Age >=18 years

          -  For paclitaxel combination arms: histologically or cytologically documented
             adenocarcinoma of the breast with locally recurrent or metastatic disease

          -  For docetaxel combination arms: histologically or cytologically documented
             adenocarcinoma of the breast with locally recurrent or metastatic disease or
             histologically documented advanced (Stage IV) or recurrent NSCLC

          -  For participants with breast cancer: HER2-negative disease as defined by local
             clinical guidelines

          -  Participants with NSCLC to be treated with docetaxel need to have received at least
             one prior anti-cancer treatment regimen in an advanced setting and to have docetaxel
             be considered appropriate treatment

          -  Evaluable or measurable disease per response evaluation criteria in solid tumors
             (RECIST) v.1.1

          -  Life expectancy >=12 weeks

          -  Eastern cooperative oncology group (ECOG) performance status of 0 or 1 at screening

          -  Adequate hematologic and end organ function

          -  Use of highly effective form of contraception

        Exclusion Criteria:

          -  Prior anti-cancer therapy

          -  Prior treatment with phosphoinositide 3-kinase (PI3K) inhibitor

          -  Known significant hypersensitivity to any components of study treatment

          -  Grade >=2 peripheral neuropathy

          -  Type 1 or Type 2 diabetes

          -  Grade >=2 hypercholesterolemia or hypertriglyceridemia

          -  Congenital long QT syndrome

          -  Active congestive heart failure or ventricular arrhythmia